The treatment of ductal carcinoma in situ of the breast (DCIS) has changed dramatically during the last decade. Material and Methods: In a review article, prospective randomized and retrospective studies of different treatment options of DCIS are evaluated to define the new role of radiotherapy. Results: Until a few years ago, total mastectomy was the standard treatment of DCIS achieving a 95−98% cure rate. Three randomized studies show that adjuvant radiotherapy following local excision significantly reduces the rate of invasive and noninvasive recurrences by 40−60%, thus making breast conservation possible. Retrospective studies evaluated prognostic factors (tumor size; age; margin width, presence of necrosis; grading) in order to define subgroups of patients whom adjuvant radiotherapy can be safely spared. Adequately excised tumors with favorable grading and not associated with necrosis are potential candidates. Further evaluation in prospective randomized studies is, however, required. Conclusion: Radiotherapy is an essential part of breast-conserving treatment of DCIS to achieve sufficient local control. 
Introduction
Ductal carcinoma in situ (DCIS) of the breast is characterized by a proliferation of malignant epithelial cells without perforation of the basal membrane in the glandular duct of the breast. Since more patients have been taking part in mammography screening, the frequency of this tumor has increased. While the percentage of DCIS contributing to the total number of mammary carcinomas recorded in the Tumor Register of Rostock until 1990 was < 1%, this has continuously increased since then to reach the present level of 5-8% of all mammary car-Strahlenther Onkol 2004 · No. 11 © Urban & Vogel cinomas. In studies done in the USA, the DCIS percentage of carcinomas detected using mammography was even up to 20% [3, 22] . The optimal treatment of DCIS has been a matter of controversial discussion in recent years. Until a few years ago, mastectomy was the standard procedure [3] . Since the work done, among others, by Rolf Sauer [32] [33] [34] showed that, in the case of invasive carcinoma, breast-conserving therapy was equivalent to mastectomy in early stages and therefore more and more patients with invasive cancer were treated by breast-conserving therapy [16, 23] , this method was also tested for noninvasive DCIS. In this regard, the role of radiotherapy was investigated in three randomized studies in recent years. Consequently, on the basis of the results of these studies and the current discussion in the literature an overview of the possibilities, indications and problems of radiotherapy in the treatment of DCIS will be presented here.
Mastectomy
Until a few years ago, mastectomy was the standard treatment of DCIS. Retrospective studies show that in > 95% of the cases the disease can be cured [41] . The local recurrence rate is between 0% and 12% in retrospective series; in a meta-analysis by Boyages et al. [6] , it amounted to 1.4%. The few recurrences after mastectomy were traced back to either the presence of an undetected invasive carcinoma, the development of a new mammary carcinoma in the glandular tissue of the breast which remained behind after mastectomy, or a residual DCIS focus.
The treatment of DCIS using mastectomy has never been compared in prospective randomized studies of breast-conserving therapy. For this reason, only retrospective data are available. According to a meta-analysis done by Boyages et al. [6] from published retrospective and prospective studies, the local recurrence rate is lowest after mastectomy at 1.4% (95% confidence interval [CI] 0.7-2.1%), and highest after tumorectomy alone at 22.5% (95% CI 16.9-28.2%). Using additional irradiation, the recurrence rate after breast-conserving therapy was able to be decreased to 8.9% (95% CI 6.8-11%); the low level after mastectomy could, however, not be achieved. Presumably, the patients' prognosis would not be compromised by the higher local recurrence rate; in randomized studies survival rates following breast-conserving therapy of 98-99% after 5 years and 86% after 12 years were determined [12, 20, 46] , and after 15 years a survival rate of 92% following operation and irradiation was found in retrospective studies [42] . Therefore, it will also be impossible in the future to conduct a suitable randomized study.
Breast-Conserving Therapy and Radiotherapy
The goal of radiotherapy is a reduction of the local recurrence rate, which can amount to up to 40% after excision alone. An improvement in survival rate is not possible with the primary prognosis already excellent. Meanwhile, three randomized studies on the significance of radiotherapy have been published:
• the NSABP B-17 study [10, 12] , • the EORTC 10853 study [20] , • and the UKCCCR study [46] .
With these, the data of a total of 2,372 randomized patients are available. Radiotherapy was done in all three studies consistently; the residual breast was irradiated with single doses of 2 Gy up to a total dose of 50 Gy.
The studies do, however, differ in essential points (Table 1): • the inclusion criteria: in the NSABP B-17 study patients with diffuse calcifications were included, as long as there was no indication of an invasive carcinoma. By contrast, in the EORTC study only patients with a tumor diameter of up to 5 cm and without evidence of an invasive carcinoma or Paget's cancer were included. The age limit was 70 years. The UKCCCR study took in patients with a DCIS that had been detected within the framework of preventive mammography, as well as patients with a microinvasive carcinoma (< 1 mm). An age limit was not applied in the NSABP B-17 and the UKCCCR study.
• the median follow-up period: it ranges from 10 (NSABP B-17 study) to 4.33 (UKCCCR study) and 4.25 years (EORTC 10853 study).
• the patients' age: while in the NSABP B-17 study 33% of the patients were < 50 years of age, this age group amounted to only 9.5% of the patients in the UKCCR study. In the EORTC study the patients' median age was 53 years, so that here, too, a significant percentage of the patients were < 50 years. Although all three studies demanded a complete tumor resection, additional histopathologic analyses in the NSABP B-17 study revealed affected/insecure resection margins in 17% of the patients [13] ; in the EORTC study they were detected in 21% [4] . The UKCCCR study refers to very precise instructions on the histopathologic procedures and therefore assumes the percentage of affected resection margins to be minimal; precise figures are not given. Despite these differences all three studies provide a homogeneous result. In all three studies the rate of recurrences in the breast was significantly decreased (see Table 1 ). The relative reduction of the risk of local recurrences after radiotherapy is between 40% and 60%. The corresponding applies to the relative rate of invasive local recurrences, which were also reduced by 40-60%. In regard to noninvasive DCIS, both the NSABP B-17 study and the UKCCCR study show a significant reduction. Within the framework of the EORTC study, the significance level for DCIS recurrences of p = 0.06 was not achieved. In particular, the 12-year results of the NSABP study indicate that this advantage remains constant.
Expectedly, the survival rates and the frequency of distant metastases were not changed by radiotherapy. The rate of contralateral breast tumors did not increase in either the NSABP study or the UKCCCR study. However, in the EORTC study, 3% contralateral tumors were found in the irradiation arm, whereas the control arm showed 1% only. This difference is, at p = 0.01, statistically significant. In the further course of the study this difference was balanced out again.
In summary, the three randomized studies show that the local recurrence rate of invasive and noninvasive carcinoma can be significantly reduced by radiotherapy.
Arguments Against Radiotherapy
Even if radiotherapy does improve the local recurrence rate in randomized studies, the following arguments are brought forward against radiation treatment: • The DCIS is not a malignant underlying disease, but is typified by an excellent long-term prognosis. This means that the risk of tumor induction through radiotherapy must be considered. This risk does not play a role in the first 10-12 years, as the randomized studies show. However, we have little data on the time thereafter. In a retrospective analysis, Gao et al. [15] examined 134,501 patients with invasive carcinoma or DCIS that had been taken up into the "National Cancer Institute's SEER program". Of these patients, 37,379 were submitted to irradiation. After 15 and 20 years the actuarial rates of contralateral breast tumors were 8.9% and 11.8% without and 10.2% and 13.4% with radiotherapy, corresponding to an absolute increase of 1.6% after 20 years. Taking the entire time period into account, this increase was not significant, however, for the time period beginning 5 years after treatment. Further data from the literature is contradictory. The authors of the study cited above proceed from the assumption of a small increase which, in their opinion, should not influence the clinical decision for radiotherapy.
• Irradiation could lead to a fibrosis of the breast, so that the posttreatment follow-up is more difficult and the evaluation of the mammogram is impeded. However, experienced radiologists only rarely have problems in this respect due to their experience with breast-conserving therapy nowadays.
• Other side effects of irradiation in respect to the heart or the lungs should no longer be an argument, as these organs are not or only minimally affected by three-dimensional radiotherapy [37, 44] .
• Because of the irradiation, necessary operations arising in the case of a recurrence such as a "skin-sparing" mastectomy with subsequent reconstruction are more difficult. This may be true for individual cases; from the large randomized studies on breast-conserving therapy with irradiation there was, however, no report of more difficult healing processes after surgery for recurrence. • In the case of an invasive recurrence, radiotherapy is no longer available. The therapy of choice in invasive recurrences is mastectomy; in regulated follow-up these tumors are detected mostly < 5 cm, so that a postoperative irradiation is generally not necessary. Irradiation of the lymphatic drainage areas is not affected by this [1, 14, 17, 35] .
• Another argument against radiotherapy is the 6-week treatment time and the cost of the treatment at about D 2,000-4,000.-. However, the treatment period in comparison to the utility of radiotherapy plays only a subordinate role, as some of the patients, on the long run, are spared renewed therapy by irradiation. The cost of irradiation at D 2,000-4,000.-must be seen in comparison to the potential costs of a treatment for recurrences or the costs of a drug treatment, for instance chemotherapy or hormone therapy, which are significantly higher than those of a radiation treatment. In summary, most of the arguments are easy to rebut; the potential carcinogenicity of irradiation must be taken seriously. There are too little long-term data in this regard for a definitive statement and we are obligated to gather this information.
Prognostic Factors for the Occurrence of Local Recurrences
In retrospective and prospective studies different parameters were investigated which might be connected to the frequency of the local recurrence risk.
Tumor Size
The tumor size is not a sure prognostic parameter for a local recurrence in most of the studies. Only the studies by Silverstein et al. [38, 39] (see below), Neuschatz et al. [25, 26] , and
Provenzano et al. [29] found a connection. For instance, Neuschatz et al. [25] observed that, for tumors < 15 mm, no local recurrences appeared, regardless whether they had been irradiated or not; for tumors which were larger, the local recurrence rate was 36% without and 21% with radiotherapy (p = 0.03). However, both randomized studies [4, 13] found no significant difference between the local recurrence rate for tumors < and > 1 cm, whether irradiated or not. This is supported by the meta-analysis of Boyages et al. [6] , wherein a local recurrence rate without irradiation of 18.1% for tumors with a size of 0-1 cm and 21.3% for tumors > 10 mm was reported. After irradiation there are only two studies given in this meta-analysis, so that their statement cannot be referred to. Retrospective studies of Solin et al. [42, 43] , Cutuli et al. [8] , and Rodrigues et al. [30] confirm that, after irradiation, tumor size has no influence on the local recurrence rate. The restricting point must be made, however, that nearly all of the studies only covered tumors up to a size of 2 cm, whereby the percentage of tumors < 1 cm in the histopathologic evaluations of the randomized studies was approximately 70%. Therefore, statements on tumors > 2 cm are not possible. It is conspicuous in both randomized studies that patients whose tumors were > 1 cm profited more from irradiation, as the reduction of the local recurrence rates for tumors < 1 cm was 30-40%; for tumors > 1 cm, however, it was 50-70%.
Resection Margin
Many authors consider the resection margin to be the most important prognostic parameter for a local recurrence as it is for invasive breast cancer [36] ; many questions remain unanswered, though. There are no fixed rules which criteria should be used to determine a free resection margin. In the EORTC study [4] patients with a free resection margin without irradiation had a reduced local recurrence risk at approximately 23% (estimate from the Kaplan-Meier curves at 8 years) in comparison to patients with an insecure or affected resection margin at 35%; in the NSABP study [13] the respective values were 29% and 39% (absolute values); through an additional irradiation the differences remain; the distances between them are, however, reduced: in the EORTC study approximately 12% versus 18%; in the NSABP B-17 study at 13% versus 17% (absolute values). In the EORTC study the resection margin is an independent prognostic parameter with p = 0.02; in the NSABP B-17 study the significance level is just missed at p = 0.06. Also in the NSABP B-24 study [11] , tumors with a positive resection margin have a 1.8 times higher risk of local recurrences; tamoxifen, in addition, leads to a risk reduction of 21% in free resection margins and of 47% in tumor-afflicted resection margins.
In retrospective studies this is confirmed. Silverstein et al [40] reported that patients with a resection margin > 10 mm had a local recurrence rate of 4% at 8 years independently of whether they had been irradiated. Patients with a resection margin of 1-9 mm had a recurrence rate of 20% without and 12% with radiotherapy (p = 0.24); with resection margins < 1 mm the values were 58% without and 30% with radiotherapy (p = 0.01). Neuschatz et al. [25] observed a recurrence rate of 10.9% after excision alone and with a resection margin of > 1 mm; after irradiation the figure was 4.9% (not significant at this small number of cases). In a subsequent study, this group of authors [26] found a resection margin of 1 mm to be sufficient. Tunon-de-Lara et al. [45] also discovered the tumor-afflicted resection margin after excision alone as an independent prognostic parameter.
In a multicentric study, Solin et al. [42] observed a lower local recurrence rate after additional irradiation at 9% for free resection margins as compared to 24% for afflicted resection margins (p = 0.03), which was confirmed by two French studies [8, 45] . By contrast, Rodrigues et al. [30] , in a monocentric study, and Solin et al. [43] , in a first evaluation of the multicentric analysis, found no indication of this.
In summary, the resection margin after surgery is an important parameter for the evaluation of the local recurrence risk; it is, however, unclear how large the resection margin must be: 1 or 10 mm. Through an additional irradiation, the negative effect of an afflicted resection margin does remain, but becomes less or, in some part, no longer measurable. Some work groups use an interstitial or percutaneous boost for tumor-afflicted resection margins [24] as usual in invasive breast cancer [18, 19, 28] or recurrent tumors [21] . Whether this actually leads to a further reduction of the local recurrence rate, as it does for invasive carcinoma, has not yet been proven.
Age
As in the experience of invasive mammary carcinoma, younger women have a higher local recurrence rate. In women < 40 years the EORTC study [4] showed a twofold increase in the recurrence rate as compared to older women as an independent prognostic parameter. In the NSABP B-24 study, women < 50 years also display an increase in risk by a factor of 2 [12] . This is confirmed by a range of retrospective series [8, 39, 42, 45, 47] (see below). In an overview, Vicini & Recht [48] found that younger women also more often have other unfavorable prognostic factors such as necroses, that they display unfavorable degrees of differentiation and have more advanced tumors. Also, for cosmetic reasons younger women forgo more extensive tumor resections. Young women have a greater frequency of invasive recurrences. There are, however, no data which show that the prognosis of this patient group is improved by mastectomy.
Necroses
The occurrence of necroses is associated with an increase in the local recurrence risk. This is confirmed by both randomized and nonrandomized studies. In the NSABP B-17 study [13] evidence of necroses was the most important independent prognostic parameter, in particular when irradiation was waived. The local recurrence rate in the presence of necroses was 40% as opposed to 23% (absolute values; no irradiation) without evidence of necroses; after additional irradiation these values were at 14% and 13%. In the EORTC study [4] the univariate analysis showed a significant relationship; in the multivariate analysis the histological architecture was decisive. Also in the NSABP B-24 study, the appearance of necroses increased the local recurrence risk by a factor of 1.8 [12] .
In retrospective analyses, Provenzano et al. [29] and Silverstein et al. [37, 38] (see below) were able to confirm this; however, Neuschatz et al. [26] , Solin et al. [43] , and Rodrigues et al. [30] could not. Many of the retrospective studies do not indicate whether this factor was evaluated or not.
Degree of Differentiation
In multivariate analyses, both randomized studies found no influence of the degree of differentiation on the frequency of local recurrences. While it was clear in the EORTC study [4] , with p = 0.56, the effect was only borderline in the NSABP study [12] at p = 0.07.
The meta-analysis of Boyages et al. [6] shows a low recurrence rate of 4.9% without irradiation and at low nuclear grading as compared to 22.7-29.2% at intermediate or high nuclear grading. With additional irradiation these differences become significantly lower at 11.6% (high nuclear grade),
8.2% (intermediate grade), and 3.7% (low grade).
In retrospective studies, Provenzano et al. [29] , Silverstein et al. [37, 38] (see below), and Roka et al. [31] confirm this, whereas Neuschatz et al. [26] , de Mascarel et al. [9] , and Rodrigues et al. [30] do not. Tunon-de-Lara et al. [45] found an influence of the degree of differentiation for tumors which had only been excised, but not after additional irradiation.
Must All Patients with Ductal Carcinoma in Situ be Irradiated?
The three randomized studies show that even without radiotherapy, 79-84% of the patients remained free of recurrences. The question therefore arises whether all patients should indeed undergo radiotherapy, or whether the choice of specific parameters (see above) allows to select patients with a particularly low risk of local recurrences, so that irradiation is not necessary.
For this reason, the work group associated with Silverstein [38] [39] [40] [41] proposed the "van Nuys prognostic index" in 1995. In this index the decisive parameters were, originally, the size of the tumor, the width of the resection margin, and the presence of comedo necroses as well as the grading. Using a point system, the patients were divided into three groups which were then recommended a tumorectomy, a tumorectomy with radiotherapy, or a mastectomy. In 2001, a modification was done in that the patients' age was included. The data on the development of these scores are based on a total of 1,115 patients that were determined either with a mastectomy (n = 401), a breast-conserving therapy without irradiation (n = 433), or a conservative therapy with irradiation (n = 281). In the analysis the tumor size, the age, the resection width, the degree of differentiation, and the presence of necroses were shown to be independent prognostic parameters. In the group with the best prognosis, which was recommended a tumorectomy alone, the tumor-free survival was 98%. In the group with a medium probability of recurrence, the tumor-free survival rate after 10 years was 60% with excision alone and 80% with excision and radiotherapy. In the latter cases the authors recommend a tumor excision with irradiation. In the group with the worst prognosis, nearly all of the patients who were only excised suffered a local recurrence. After additional radiotherapy, the tumor-free survival rate after 10 years is 60%.
Since then, a heated discussion on the value of the van Nuys score has ensued. The adoption of this score into daily routine is problematic for a number of reasons.
• It is a case of retrospective data which has never been tested in prospective studies. The follow-up periods are different: after tumorectomy the median is 65 months, as compared to 105 months for the group treated with tumorectomy and irradiation. The tumor sizes also differ: for a resection margin > 10 mm, the median tumor size was 12.5 mm in the radiotherapy arm but 9 mm after tumorectomy alone. In the case of smaller resection margins of 1-3 mm, the difference in median tumor size was between 14.5 mm (tumorectomy and radiotherapy) and 8 mm (tumorectomy alone). Within the study there were also changes in the irradiation concept. Up to 1994 the percutaneous irradiation dose was set at 55.0 Gy, which is higher than that used in later years. In addition, an interstitial boost was administered in the early years, especially when the tumor margins were involved [24] . • Other work groups which used the van Nuys score on their collectives were not able to reproduce the data. For instance, de Mascarel et al. [9] found a high recurrence risk at about 9% in their low-risk group without irradiation. Boland et al. [5] determined that 70% of their patients were at medium risk and, therefore, very few patients could be spared radiotherapy. In the EORTC study [4] , the van Nuys score was only significant in univariate but not in multivariate analysis.
In the NSABP study [13] there were no differences in the rate of local recurrences according to the van Nuys pathologic classification.
• All three randomized studies show that patients with an increased risk of recurrence (e.g., young women; tumor-afflicted resection margins, appearance of comedo necrosis) especially benefit from an adjuvant irradiation. However, the local recurrence risk is also significantly reduced in patients with a favorable risk profile. The extent to which patients with a low risk of local recurrences can do without an adjuvant irradiation is being determined within the framework of an RTOG study. However, a prospective study in which irradiation was forgone in a targeted manner was prematurely stopped. In this study patients with a DCIS grade 1 or 2, a tumor size < 2.5 cm, and a resection margin of at least 1 cm were included. After a median
follow-up period of 40 months, the 5-year local recurrence rate was 12.5% at an annual rate of 2.5% [49] .
Ductal Carcinoma in Situ and Antihormonal Therapy
The situation of the data on the adjuvant administration of tamoxifen is unclear. Both studies published until now show partly contradictory results.
The NSABP B-24 study [11, 12] recruited 1,804 patients who, according to tumor excision, were either given radiotherapy only or received additional tamoxifen (20 mg/m 2 for 5 years). Contrary to the NSABP B-17 study, patients whose resection margins were afflicted with tumors were included. After 7 years the event free survival in the OP + RT + tamoxifen arm was 83% as opposed to 77.1% in the OP + RT arm (p = 0.002), corresponding to a reduction of 27%. This could be traced to a significant reduction in invasive carcinoma and contralateral tumors; an effect on the noninvasive ipsilateral DCIS recurrences was not recorded. The tamoxifen effect was especially pronounced when the margins of the incision were afflicted with tumors or the DCIS displayed comedo necroses, i.e., collectively in patients with a high risk of local recurrences. Further analyses revealed that only patients whose tumors had estrogen receptors showed a benefit [2] .
Contradictory results were yielded by the UKCCCR study [46] , which randomized 1,576 patients with regard to tamoxifen. Tamoxifen without irradiation led to a significant reduction of noninvasive DCIS tumors, both ipsi-and contralaterally, but not of the invasive tumors. If the patients had been irradiated in addition, the effect of tamoxifen was no longer verifiable ipsilaterally (neither for invasive nor noninvasive tumors).
In this way, both studies lead to different results: • NSABP B-24: reduction of invasive recurrences; additional effect with radiotherapy; • UKCCCR study: reduction of noninvasive recurrences; no additional effect with radiotherapy. The authors of the UKCCCR study ascribe this difference to the fact that the risk profile of the patients included in both studies was different. In the NSABP B-24 study mostly women < 50 years of age were included, in the UKCCCR study, on the other hand, women > 50 years of age. In the NSABP B-24 study patients with positive incision margins were included; in the UKCCCR study this was to be avoided. In the NSABP study all patients received radiotherapy, as compared to only 33% in the UKCCCR study.
Taking this into account, both studies point out that women < 50 years of age benefited from the additional administration of tamoxifen (hazard ratio 0.52-0.62) in comparison to women > 50 years (hazard ratio 0.85-0.95).
When tamoxifen is taken, the additional development of gynecologic tumors is feared, in particular endometrial carcinoma. After 5 and 7 years, respectively, both studies found that the tamoxifen group had more endometrial carcinomas, but the results were not significant. In summary, both studies indicate that tamoxifen can reduce the risk in patient groups with a high risk of local recurrences, i.e., age < 50 years, comedo necroses, tumor-afflicted incision margins, and estrogen receptor-positive tumors. However, there is no indication that the other patient groups, in particular women > 50 years of age with good prognostic parameters, benefit from adjuvant administration of tamoxifen in addition to radiotherapy.
Details in the Guidelines for the "Use of Radiotherapy"
In the guidelines of the NCI (www.meb.uni-bonn.de/cancer. goc/CDR0000062787.html), breast-conserving therapy and irradiation without tamoxifen are named at the top of the list; second on the list is mastectomy without the application of tamoxifen. According to these guidelines, radiotherapy can only be left out within the framework of a study. This was also confirmed in a recently published review [7] .
In the guidelines of the German Cancer Society (www. krebsgesellschaft.de) "postoperative irradiation" is "in general" seen as being indicated. However, it is pointed out that in the case of a tumor size < 2 cm, a low grade and a 10-mm safety clearance, irradiation can be forgone. The guidelines of the German Cancer Society are, in this sense, more restrictive than the NCI recommendations.
In the guidelines of the AGO (www. ago-online.de), postoperative irradiation is confirmed as having an evidence level of Ib. According to these guidelines, the value of radiotherapy is questionable in cases of a tumor < 2-3 cm in diameter, a resection margin > 10 mm and a low nuclear grading or a van Nuys prognostic index ≤ 4. These guidelines point out explicitly that side effects and disadvantages of irradiation are to be weighed against the risk reduction.
On a critical note it must be pointed out that the German guidelines rely on retrospective data and not on prospective randomized studies in their choice of the criteria dictating when irradiation can be forgone. In the statements on the degree of differentiation and the resection margin this is readily understandable. This does not apply, however, to the tumor size; here, there are hardly any data on tumors > 2 cm; the randomized studies did not find any influence of tumor size. In addition, at least 70% of the tumors in the randomized studies were uniformly of a size < 2 cm. Unfortunately, the patients' age, which displayed a clear influence in almost all other studies, was not taken into account here; patients < 40 years of age should, on the basis of their high rate of recurrence, always be irradiated. The corresponding recommendation applies to the appearance of necroses; here, too many studies showed an influence on the recurrence rate.
Conclusion
Through adjuvant radiotherapy, the local recurrence risk for DCIS can be reduced by 40-60%. Patients with an increased risk of recurrences (e.g., women < 50 years, tumor-afflicted resection margins, appearance of comedo necroses) especially benefit from an adjuvant irradiation. However, the frequency of local recurrences is also reduced in cases of a favorable risk profile. Questions still open are: • For which patient group, given prognostically favorable parameters, can treatment be performed without irradiation? How large must the tumor-free resection margin be? 1 or 10 mm? • As currently investigated for invasive breast cancer [27] , can the treatment volume be confined to the tumor bed in some patients with favorable prognostic factors? • To which patients should additional tamoxifen be prescribed? To all patients with estrogen receptor-positive tumors, or only if additional risk factors are present (e.g., age < 50 years; comedo necroses)? • Should patients with unfavorable risk parameters (e.g., tumor-afflicted resection margin) be given an interstitial or percutaneous boost?
